Theranica Bio-electronics announced positive top-line results from a double-blind, randomized, placebo-controlled, multicenter clinical trial to evaluate efficacy and safety of Nerivio for the treatment of episodic and chronic migraine.
According to a company release, the study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients treated with Nerivio — a smartphone-controlled, wearable device — compared with placebo.
“There is a growing recognition that certain chronic pain diseases, such as migraine,